Clinical reference Biomarker Directory
Back to directory

Amyloid Beta42

Emerging

The Aβ42/Aβ40 ratio is central to modern Alzheimer's diagnosis and now gatekeeps eligibility for anti-amyloid antibody treatment.

Also known as A-beta 42 amyloid-beta 1-42
In plain language

Aβ42 is a protein fragment that builds up as plaques in Alzheimer's disease. A blood test measuring its ratio to a related protein has become genuinely important recently, since confirming this pathology is now required before prescribing the newest Alzheimer's drugs.

Biomarker & context

Amyloid beta 42 (Aβ42) is a peptide fragment that aggregates into the amyloid plaques characteristic of Alzheimer's disease; the ratio of Aβ42 to Aβ40 in blood or CSF is a key biomarker of amyloid pathology.

What it indicates

A low Aβ42/Aβ40 ratio indicates amyloid plaque accumulation in the brain, supporting an Alzheimer's disease diagnosis; this is genuinely one of the most active current areas in all of medicine given recent treatment developments.

Diagnosis & clinical testing

The 2024 Alzheimer's Association revised diagnostic criteria formally incorporate blood-based biomarkers, and a plasma p-tau217/Aβ42 test received FDA approval; amyloid-positivity confirmation via this ratio is now a prerequisite for prescribing the newer anti-amyloid drugs (lecanemab, donanemab).

Guiding treatment

This blood test increasingly gatekeeps access to anti-amyloid antibody treatment rather than functioning as a purely diagnostic curiosity — periodic biomarker re-testing during treatment can also help determine whether amyloid pathology is re-accumulating and whether to restart antibody therapy after a treatment course.

Clinical significance

A rapidly evolving area given very recent (2024-2025) diagnostic criteria updates and new FDA-approved blood tests.

References
  1. PMC. (2025). Evolving Alzheimer's Disease Clinical Practice: Updated Diagnostic Criteria, Fluid Biomarkers, and Special Considerations for Anti-Amyloid Therapies.
  2. PMC. (2025). Blood-Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer's Disease.